Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...

Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate ...

However, there is currently no consensus on the standard of care for this population. Durvalumab, an immune checkpoint ...

Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable ...

Discover the trials that have shown why Predictive biomarkers are expected to play a pivotal role in further enhancing ...

In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer ...

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report.

This approval establishes the use of Olaparib in combination with Durvalumab as a maintenance treatment for adult patients ...

AstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and ...

AstraZeneca Pharma India has gained approval from India's drug regulator to import cancer treatment drug Lynparza for sale. The tablets are for use in combination therapy for patients with specific ...

Bangalore: AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from ...

The monoclonal antibody cetuximab (Erbitux) was more effective than a newer drug, the immune checkpoint inhibitor medicine durvalumab (Imfinzi), in fighting head-and-neck tumors, the trial found.